TY - JOUR
T1 - A self-administered immersive virtual reality tool for assessing cognitive impairment in patients with cancer
AU - Zeng, Y.
AU - Guan, Q.
AU - Su, Y.
AU - Huang, Q.
AU - Zhao, J.
AU - Wu, M.
AU - Guo, Q.
AU - Lyu, Q.
AU - Zhuang, Y.
AU - Cheng, Andy S. K.
PY - 2023/3
Y1 - 2023/3
N2 - Objective: This study was aimed at exploring the feasibility and validity of a self-administered immersive virtual reality (VR) tool designed to assess cognitive impairment in patients with cancer. Methods: In a cross-sectional survey study, an immersive tool was used to rate the previously recommended core assessment domains of cancer-related cognitive impairment—comprising attention, verbal learning memory, processing speed, executive function and verbal fluency—via an interactive VR scenario. Results: A total of 165 patients with cancer participated in this study. The participants' mean age was 47.74 years (SD = 10.59). Common cancer types included lung, liver, breast and colorectal cancer, and most patients were in early disease stages (n = 146, 88.5%). Participants’ performance in the VR cognition assessment showed a moderate to strong positive correlation with their paper-and-pencil neurocognitive test results (r = 0.34–0.76, P < 0.001), thus indicating high concurrent validity of the immersive VR cognition assessment tool. For all participants, the mean score for the VR-based cognition assessment was 5.41 (SD = 0.70) out of a potential maximum of 7.0. The mean simulation sickness score for the VR-based tool, as rated by the patients, was 0.35 (SD = 0.19), thereby indicating that minimal simulation sickness occurred during the VR-assisted cognition assessment. Conclusions: Given its demonstrated validity, and the patients’ high presence scores and minimal sickness scores, this VR-based cognition assessment tool is a feasible and acceptable instrument for measuring cognitive impairment in patients with cancer. However, further psychometric assessments should be implemented in clinical settings.
AB - Objective: This study was aimed at exploring the feasibility and validity of a self-administered immersive virtual reality (VR) tool designed to assess cognitive impairment in patients with cancer. Methods: In a cross-sectional survey study, an immersive tool was used to rate the previously recommended core assessment domains of cancer-related cognitive impairment—comprising attention, verbal learning memory, processing speed, executive function and verbal fluency—via an interactive VR scenario. Results: A total of 165 patients with cancer participated in this study. The participants' mean age was 47.74 years (SD = 10.59). Common cancer types included lung, liver, breast and colorectal cancer, and most patients were in early disease stages (n = 146, 88.5%). Participants’ performance in the VR cognition assessment showed a moderate to strong positive correlation with their paper-and-pencil neurocognitive test results (r = 0.34–0.76, P < 0.001), thus indicating high concurrent validity of the immersive VR cognition assessment tool. For all participants, the mean score for the VR-based cognition assessment was 5.41 (SD = 0.70) out of a potential maximum of 7.0. The mean simulation sickness score for the VR-based tool, as rated by the patients, was 0.35 (SD = 0.19), thereby indicating that minimal simulation sickness occurred during the VR-assisted cognition assessment. Conclusions: Given its demonstrated validity, and the patients’ high presence scores and minimal sickness scores, this VR-based cognition assessment tool is a feasible and acceptable instrument for measuring cognitive impairment in patients with cancer. However, further psychometric assessments should be implemented in clinical settings.
UR - https://hdl.handle.net/1959.7/uws:76014
U2 - 10.1016/j.apjon.2023.100205
DO - 10.1016/j.apjon.2023.100205
M3 - Article
VL - 10
JO - Asia-Pacific Journal of Oncology Nursing
JF - Asia-Pacific Journal of Oncology Nursing
IS - 3
M1 - 100205
ER -